title: [Local effects of transdermal treatment with rotigotine].
abstract: BACKGROUND
  Rotigotine is the first transdermal non-ergolinic dopaminergic agonist used in the treatment of Parkinson's disease. It has several important advantages such as once-daily administration, absence of interactions with food, steady levels in plasma and continuous dopaminergic stimulation. Although its systemic side effects are similar to those seen in other dopaminergic agonists, rotigotine also has local side effects derived from the site of application. The aim of this paper is to review those local problems.
  
  
  METHODS
  A retrospective analysis was carried out in order to identify the first 165 patients treated with rotigotine. Patients with intracranial lesions, psychiatric pathology or dementia were excluded. Patients were evaluated before and at two, four and six months after beginning treatment with rotigotine.
  
  
  RESULTS
  In all, 94 males and 71 females were identified, with an average age of 65.2 and an average rotigotine daily dose of 11.3 mg. Local side effects were present in 21 patients and they were usually mild. Two patients abandoned the treatment because of these local adverse events, presenting erythema and prurigo. Thirty patients complained about lack of adherence of the patch, specially when it was hot, and 36 about the formation of wrinkles in the patch. None of these problems was associated to motor fluctuations or other complications.
  
  
  CONCLUSIONS
  Local complications of transdermal rotigotine are mild but frequent. We consider it is necessarily to take them into account to get a better treatment of patients suffering from Parkinson's disease.
authors.affiliation: Servicio de Neurología, Hospital Universitario Puerta de Hierro-Majadahonda, 28035 Majadahonda, Madrid, Spain. pedro.bermejo.v@gmail.com
authors.forename: Pedro Emilio
authors.initials: PE
authors.lastname: Bermejo
authors.forename: María Ascensión
authors.initials: MA
authors.lastname: Zea
authors.forename: Lucía
authors.initials: L
authors.lastname: Alba-Alcántara
authors.forename: Cristina
authors.initials: C
authors.lastname: Ruiz-Huete
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004868:Equipment Failure; D004890:Erythema / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced*; D010342:Patient Acceptance of Health Care; D012189:Retrospective Studies; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D057968:Transdermal Patch
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine